Mean NT-proBNP levels declined in both groups during the study, but at week 12 and 26 the NT-proBNP level was 13% and 15% lower in the empagliflozin group, respectively, after adjustment for baseline NT-proBNP concentration, gender, and diabetes status (P = 0.026). This evidence concerns the gene NPPB and diabetes mellitus.